期刊
RADIOLOGY
卷 270, 期 2, 页码 574-582出版社
RADIOLOGICAL SOC NORTH AMERICA
DOI: 10.1148/radiol.13121824
关键词
-
Purpose: To study chest computed tomography (CT) in tyrosine kinase inhibitor (TKI) treatment of epidermal growth factor receptor (EGFR)-mutant adenocarcinoma. Materials and Methods: This retrospective study was approved by the institutional review board. Informed consent was waived. One hundred thirty consecutive patients with stage IV adenocarcinoma and EGFR mutations at a single tertiary center from November 2004 to April 2010 were enrolled retrospectively. CT images were analyzed with Response Evaluation Criteria in Solid Tumor guidelines. Target lesions were classified by size, type, axial location, and metastasis. Patients were followed after TKI therapy, and treatment response was classified as partial response, stable disease, or progressive disease. A Cox proportional hazards model was used to correlate baseline CT features and EGFR mutations with progression-free survival (PFS) and overall survival. Results: All patients underwent TKI therapy after identifying exon mutations in the EGFR gene, comprising exon 19 deletion (19del) (n = 77), L858R (n = 43), and exon 18 (n = 10). Outcomes were partial response (n = 103), stable disease (n = 22), and progressive disease (n = 5). In univariate analysis, PFS was significantly longer with small lesions (hazard ratio [HR], 1.02; 95% confidence interval [CI]: 1.01, 1.03; P < .01), nodular main lesions (HR, 0.55; 95% CI: 0.34, 0.88; P = .01), or peripheral lesions (HR, 0.62; 95% CI: 0.42, 0.93; P = .02). In univariate analysis, PFS was significantly longer with smaller lesions (HR, 1.02; 95% CI: 1.01, 1.03; P < .01), nodular main lesions (HR, 0.55; 95% CI: 0.34, 0.88; P = .01), peripheral lesions (HR, 0.62; 95% CI: 0.42, 0.93; P = .02), 19del (HR, 0.33; 95% CI: 0.14, 0.77; P = .01), or L858R (HR, 0.39; 95% CI: 0.16, 0.97; P = .04). In multivariate analysis, PFS was significantly longer with 19del (HR, 0.30; 95% CI: 0.11, 0.84; P = .02) and shorter with scattered metastases (HR, 2.25; 95% CI: 1.44, 5.51; P < .01). Conclusion: Smaller nodular lesions, peripheral lesions, and 19del relate to longer PFS after EGFR TKI treatment. (C) RSNA, 2013
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据